E. D. Crawford, MD

UCSD La Jolla CA

H Professor of Urology at the University of California San Diego and emeritus distinguished endowed Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado
Dr. Crawford has authored or coauthored over 810 scientific articles, has published seven textbooks, authored over 60 book chapters and provided more than 2,200 educational talks for patients and physicians.
. Crawford served on the board of governors, the scientific advisory board of the Southwest Oncology Group and was chairman of the Genitourinary Cancer Committee for 27 years. This group is the largest clinical trials group in the world.

Crawford's involvement in the national prostate cancer arena has been widely recognized., he was presented with a 'Freddie Award" at the AMA International Health and Medical Film Competition for the program, ITV: The Cuting Edge Medical Report (Prostate Cancer: Understanding, Diagnosing, and Defeating), which Crawford hosted with special guest, retired General Norman Schwarzkopf.
Crawford again won a prestigious 'Freddie Award" 5 years ago... He is a member of Best Doctors of America and was named Healthcare Provider of the Year in the Denver Metro area by the Denver Business Journal.
He has been recognized as one of the Best Doctors of America for the past two decades and is recognized as one of the top 20 urologists in the country, for men, by Men’s Health Magazine. In 2018 he received the honor of being named the Distinguished Alumnus of the Year from the University of Cincinnati School of Medicine. In May of 2019, he received the Presidential citation form the American Urological Association recognizing for his “tireless role in genitourinary cancer research that has benefited countless urologic cancer patients.”. Expertscape has recognized him in the top 0.02% of published authors worldwide on prostate neoplasms from 2010-2021.

Disclosure information not submitted.

Presentation(s):

• MP45-04: SelectMDx Urine Test Diagnose Men with High-Grade Prostate Cancer

  Sunday, May 15, 2022
  1:00 PM – 2:15 PM

• LBA01-07: Overall Safety and Incidences of Adverse Events by Time Interval With Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in the Phase 3 ARASENS Trial

  Sunday, May 15, 2022
  2:00 PM – 2:10 PM